safingol has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avraham, R; Israely, T; Melamed, S; Politi, B; Vitner, EB | 1 |
| Aoki, J; Doi, K; Harada, S; Hashimoto, H; Jubishi, D; Kano, K; Kurano, M; Morita, Y; Moriya, K; Okamoto, K; Okugawa, S; Saigusa, D; Sakai, E; Yatomi, Y | 1 |
2 other study(ies) available for safingol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology.
Topics: Animals; Chlorocebus aethiops; Chromatography, Liquid; COVID-19; Dioxanes; Disease Models, Animal; Gangliosides; Glucosyltransferases; Humans; Mass Spectrometry; Mice, Transgenic; Pyrrolidines; SARS-CoV-2; Sphingolipids; Sphingosine; Vero Cells; Virus Replication | 2022 |
Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries.
Topics: Ceramides; COVID-19; Cross-Sectional Studies; Glycerophospholipids; Humans; Kidney; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylglycerols; Phosphatidylserines; Retrospective Studies; SARS-CoV-2; Sphingolipids; Sphingosine | 2022 |